BioTools Innovator’s Post

𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐢𝐧𝐠 𝐎𝐛𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐨𝐧 💊 🎓 : "𝐀𝐜𝐚𝐝𝐞𝐦𝐢𝐜 𝐁𝐮𝐫𝐞𝐚𝐮𝐜𝐫𝐚𝐜𝐲" 𝐫𝐚𝐧𝐤𝐞𝐝 𝐚𝐬 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐭𝐨𝐩 𝐡𝐮𝐫𝐝𝐥𝐞𝐬 𝐢𝐧 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐈𝐏, 𝐚 𝐬𝐮𝐫𝐯𝐞𝐲 𝐰𝐞 𝐫𝐚𝐧 𝐭𝐨𝐠𝐞𝐭𝐡𝐞𝐫 𝐰𝐢𝐭𝐡 𝐍𝐢𝐜𝐤 𝐈𝐧𝐛𝐨𝐝𝐞𝐧 𝐟𝐫𝐨𝐦 𝐨𝐮𝐫 𝐭𝐞𝐚𝐦 𝐚𝐧𝐝 𝐟𝐨𝐮𝐧𝐝𝐞𝐫 𝐨𝐟 BioBeacon Finding industry partners ranked second area of concern that came through our Imagine Biotech newsletter, with industry experts and academics making up our audience. We are actively collaborating with academic institutions to accelerate a drug patents’ path to market, removing the barriers + associated investor risks. This includes securing funding sooner to ensure investor returns are viable prior to patent expiration.

❗ 𝗪𝗲 𝗵𝗮𝘃𝗲 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗹𝗮𝗯 𝘀𝘂𝗽𝗲𝗿𝗵𝗲𝗿𝗼𝘀 ❗ What superpowers do they have ❓ 🚀 They can accelerate your drug product pipeline 💡 They perform less experiments but gain more knowledge 👩🔬 They can develop platform analytical methods suitable to analyse several drug products simultaneously 🌳 They improve sustainability in your lab 💵 They reduce your costs   𝗗𝗼𝗻'𝘁 𝘁𝗲𝗹𝗹 𝗮𝗻𝘆𝗼𝗻𝗲 𝘁𝗵𝗮𝘁 𝗹𝗮𝘀𝘁 𝘁𝗵𝗶𝗻𝗴. 𝗧𝗵𝗮𝘁'𝘀 𝗮 𝘀𝗲𝗰𝗿𝗲𝘁. #innovation #technology #lab #future #DrugDevelopment

📍You are invited to join the Ori team in Boston to experience IRO® - the New Standard of CGT Manufacturing On September 17th join us, Jason C. Foster, Ori Biotech CEO and Matthew Hewitt, Vice President, CTO Manufacturing at Charles River Laboratories for an evening with IRO, where we'll be showcasing: 🔹 New real-world data from the platform 🔹 In-person IRO demos If you'd like to see an IRO in-person (trust us, you do!) and dive into the data – showing how it automates better biology, accelerates product development and helps to scale your impact, secure your place today ➡️ https://lnkd.in/ep6p_DZ3 #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

We are pleased to share that the Station 41 incubator is fully occupied with plans to expand to meet the growing demand for biotech innovation space. Learn more about the innovative companies driving this growth. https://lnkd.in/ga9tAWCK

🎥 Discover AIM Biotech on YouTube! 🎥 Are you looking to enhance your research with AIM Biotech's innovative devices? Our YouTube channel offers a treasure trove of video protocols designed to maximize the use of our products. 🔬 Step-by-Step Guides: From setting up your IdenTx platform to conducting advanced experiments with Organix, our videos provide clear, easy-to-follow instructions that ensure you get the best results. 🌟 Expert Tips: Gain insights directly from our seasoned scientists and learn the tricks of the trade to streamline your research processes. 🔄 Continuous Learning: Stay updated with our latest tutorials and product demonstrations that keep you ahead in the fast-evolving field of biotechnology. Subscribe today and start transforming the way you conduct research. Empower your experiments with the knowledge you need, whenever and wherever you need it. Visit our YouTube channel now: https://lnkd.in/gkaFpzeF #AIMBiotech #ScienceSimplified #ResearchInnovation #BiotechTutorials #YouTubeLearning

I’m constantly stepping out of my comfort zone as a new founder. It’s impossible to predict what opportunities will come you’re way when you step into this sort of role. But you have to take advantage of any and all opportunities you think will move your company in a positive direction… even if uncomfortable (most things are). Christiaan Engstrom provided me this unique opportunity where I was able to discuss both dovetail biopartners and Buzzed for Biotech, both with a mission to help fellow Bullpen members and the biotech ecosystem as a whole. Have I ever been interviewed before in a recorded session? No Was I going to pass up a professionally filmed and edited video from a prestigious group like Bullpen because I was uncomfortable with the thought? Hell no. This is GREAT marketing material! It did help that I was interviewedy by my friend Caley Anderson, MBA where we were able to exchange anxieties beforehand. 😅 Venting a bit always helps. And she did great! Give it a listen. I hope all I’m trying to build resonates with the scientific community. Interested in learning more? Have feedback? Need guidance on all things data or events planning? Let’s hop on a call. BIG announcements coming soon for both of my endeavors, so stay tuned! #biotech #lifesciences #pharma #datascience #ai #ml #founder

Public investment into the biopharma industry grew tremendously in Q1 2024, surpassing previous highs seen in 2020 and 2021. What other funding trends are defining 2024? Take a closer look at our latest research ⬇️ ▪️ IPO investment was up 254% year-over-year with 13 companies going public in Q1, versus 28 companies in all of 2023. ▪️ Similarly, there was in influx of $8.7 billion to 90 companies via secondary offerings in the first quarter of the year, nearly 5x the capital investment seen in Q1 2023. Of the group, only four companies are profitable today indicating most of these organizations are without revenue generating drugs and in need of this round of funding. ▪️ This uptick comes at a time when venture capital has slowed across the industry. Q1 venture capital flows were 35% lower than the quarterly average of 2021 and 2022. Additionally, the NASDAQ Biotechnology Index is up 8.5% over the past six months indicating strength in the stock market as well as in the industry. ▪️ Biopharma companies that go public or raise additional capital through secondary offerings typically use funds for operations with the potential to expand. This increase in public markets activity will provide additional capital for organizations to tap into. Hopefully, this will limit space give backs and lead to possible space expansions.

Public investment into the biopharma industry grew tremendously in Q1 2024, surpassing previous highs seen in 2020 and 2021. What other funding trends are defining 2024? Take a closer look at our latest research ⬇️ ▪️ IPO investment was up 254% year-over-year with 13 companies going public in Q1, versus 28 companies in all of 2023. ▪️ Similarly, there was in influx of $8.7 billion to 90 companies via secondary offerings in the first quarter of the year, nearly 5x the capital investment seen in Q1 2023. Of the group, only four companies are profitable today indicating most of these organizations are without revenue generating drugs and in need of this round of funding. ▪️ This uptick comes at a time when venture capital has slowed across the industry. Q1 venture capital flows were 35% lower than the quarterly average of 2021 and 2022. Additionally, the NASDAQ Biotechnology Index is up 8.5% over the past six months indicating strength in the stock market as well as in the industry. ▪️ Biopharma companies that go public or raise additional capital through secondary offerings typically use funds for operations with the potential to expand. This increase in public markets activity will provide additional capital for organizations to tap into. Hopefully, this will limit space give backs and lead to possible space expansions.

Public investment into the biopharma industry grew tremendously in Q1 2024, surpassing previous highs seen in 2020 and 2021. What other funding trends are defining 2024? Take a closer look at our latest research ⬇️ ▪️ IPO investment was up 254% year-over-year with 13 companies going public in Q1, versus 28 companies in all of 2023. ▪️ Similarly, there was in influx of $8.7 billion to 90 companies via secondary offerings in the first quarter of the year, nearly 5x the capital investment seen in Q1 2023. Of the group, only four companies are profitable today indicating most of these organizations are without revenue generating drugs and in need of this round of funding. ▪️ This uptick comes at a time when venture capital has slowed across the industry. Q1 venture capital flows were 35% lower than the quarterly average of 2021 and 2022. Additionally, the NASDAQ Biotechnology Index is up 8.5% over the past six months indicating strength in the stock market as well as in the industry. ▪️ Biopharma companies that go public or raise additional capital through secondary offerings typically use funds for operations with the potential to expand. This increase in public markets activity will provide additional capital for organizations to tap into. Hopefully, this will limit space give backs and lead to possible space expansions.